Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Altered TGFB1 regulated pathways promote accelerated tendon healing in the superhealer MRL/MpJ mouse.

Scientific reports·2022

Same author

Architectural control of mesenchymal stem cell phenotype through nuclear actin.

Nucleus (Austin, Tex.)·2022

Same author

FGFR2 accommodates osteogenic cell fate determination in human mesenchymal stem cells.

Gene·2022

Same author

Biological Effects of Gyrophoric Acid and Other Lichen Derived Metabolites, on Cell Proliferation, Apoptosis and Cell Signaling pathways.

Chemico-biological interactions·2021

Same author

Brd4 is required for chondrocyte differentiation and endochondral ossification.

Bone·2021

Same author

Brd4 Inactivation Increases Adenoviral Delivery of BMP2 for Paracrine Stimulation of Osteogenic Differentiation as a Gene Therapeutic Concept to Enhance Bone Healing.

JBMR plus·2021

Same journal

Quercetin suppresses TGF-β1-induced proliferation and migration of vascular smooth muscle cells via the Smad2/3/MMP-9 signaling axis.

Biochemical and biophysical research communications·2026

Same journal

Biosynthesis, characterization and biological potential of microbe-mediated silver nanoparticles using thermophilic actinomycetes, Streptomyces nigra.

Biochemical and biophysical research communications·2026

Same journal

COP9 signalosome 8 mediated autophagy drives proliferation, invasion, and metastasis in pancreatic ductal adenocarcinoma.

Biochemical and biophysical research communications·2026

Same journal

Tumor budding in colorectal cancer: partial EMT, microenvironmental remodeling, and metastatic competence.

Biochemical and biophysical research communications·2026

Same journal

Exploring the therapeutic versatility and multitarget pharmacological potential of acyl hydrazone-hydrazide scaffolds.

Biochemical and biophysical research communications·2026

Same journal

The plasma membrane H<sup>+</sup>-ATPase OSA2 negatively regulates salt tolerance in rice seedlings.

Biochemical and biophysical research communications·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 6, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Inhibiting DNA-PK_CS radiosensitizes human osteosarcoma cells.

Tewodros Mamo¹, Ann C Mladek², Kris L Shogren³

¹Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN 55902, USA.

Biochemical and Biophysical Research Communications

|March 17, 2017

Summary

This summary is machine-generated.

The DNA-dependent protein kinase catalytic subunit (DNA-PK_CS) inhibitor KU60648 shows promise for radiosensitizing osteosarcoma. This study found that blocking DNA repair with KU60648 enhances radiotherapy effectiveness in osteosarcoma cells.

Keywords:

DNA-PK DNA-PKcs KU60648 Osteosarcoma Radiosensitizers Radiotherapy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

Related Experiment Videos

Last Updated: Mar 6, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

Area of Science:

Oncology
Molecular Biology
Cancer Research

Background:

Osteosarcoma survival rates have stagnated, and current treatments cause significant side effects, necessitating novel therapeutic strategies.
Radiotherapy is generally ineffective against osteosarcoma, suggesting a need for radiosensitizing agents.
Inhibiting DNA repair mechanisms, specifically DNA-dependent protein kinase catalytic subunit (DNA-PK_CS), is a potential approach for enhancing radiosensitivity.

Purpose of the Study:

To investigate the expression of DNA-PK_CS in osteosarcoma.
To evaluate the efficacy of the DNA-PK_CS inhibitor KU60648 as a radiosensitizing agent for osteosarcoma cells in vitro.
To assess the impact of KU60648 on cell cycle distribution and DNA damage in osteosarcoma cells.

Main Methods:

Analysis of DNA-PK_CS expression in osteosarcoma tissue specimens and cell lines.
In vitro treatment of osteosarcoma cell lines (143B and U2OS) with KU60648 and radiation.
Assessment of cell viability, cell cycle distribution (G2/M phase), and DNA damage marker (γH2AX foci) following treatment.

Main Results:

DNA-PK_CS was consistently expressed in osteosarcoma tissues and cell lines.
KU60648 significantly sensitized 143B cells (1.5-fold) and U2OS cells (2.5-fold) to radiation.
Co-treatment with KU60648 led to increased G2/M phase cell accumulation (55% and 45%) and enhanced DNA damage (59% and 107% increase in γH2AX foci).

Conclusions:

The small molecule DNA-PK_CS inhibitor KU60648 demonstrates potential as a radiosensitizing agent for osteosarcoma.
Targeting DNA repair pathways via DNA-PK_CS inhibition offers a promising strategy to improve osteosarcoma treatment outcomes.
Further investigation into KU60648 as a radiosensitizer for osteosarcoma is warranted.